330 related articles for article (PubMed ID: 29897434)
1. The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
Lee S; Kim S; Park YJ; Yun SP; Kwon SH; Kim D; Kim DY; Shin JS; Cho DJ; Lee GY; Ju HS; Yun HJ; Park JH; Kim WR; Jung EA; Lee S; Ko HS
Hum Mol Genet; 2018 Jul; 27(13):2344-2356. PubMed ID: 29897434
[TBL] [Abstract][Full Text] [Related]
2. A Novel, Selective c-Abl Inhibitor, Compound 5, Prevents Neurodegeneration in Parkinson's Disease.
Kwon SH; Kim S; Park AY; Lee S; Gadhe CG; Seo BA; Park JS; Jo S; Oh Y; Kweon SH; Ma SX; Kim WR; Kim M; Kim H; Kim JE; Lee S; Lee J; Ko HS
J Med Chem; 2021 Oct; 64(20):15091-15110. PubMed ID: 34583507
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model.
Imam SZ; Trickler W; Kimura S; Binienda ZK; Paule MG; Slikker W; Li S; Clark RA; Ali SF
PLoS One; 2013; 8(5):e65129. PubMed ID: 23741470
[TBL] [Abstract][Full Text] [Related]
4. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.
Karuppagounder SS; Brahmachari S; Lee Y; Dawson VL; Dawson TM; Ko HS
Sci Rep; 2014 May; 4():4874. PubMed ID: 24786396
[TBL] [Abstract][Full Text] [Related]
5. Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration.
Brahmachari S; Ge P; Lee SH; Kim D; Karuppagounder SS; Kumar M; Mao X; Shin JH; Lee Y; Pletnikova O; Troncoso JC; Dawson VL; Dawson TM; Ko HS
J Clin Invest; 2016 Aug; 126(8):2970-88. PubMed ID: 27348587
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.
Hebron ML; Lonskaya I; Moussa CE
Hum Mol Genet; 2013 Aug; 22(16):3315-28. PubMed ID: 23666528
[TBL] [Abstract][Full Text] [Related]
7. The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease.
Karuppagounder SS; Wang H; Kelly T; Rush R; Nguyen R; Bisen S; Yamashita Y; Sloan N; Dang B; Sigmon A; Lee HW; Marino Lee S; Watkins L; Kim E; Brahmachari S; Kumar M; Werner MH; Dawson TM; Dawson VL
Sci Transl Med; 2023 Jan; 15(679):eabp9352. PubMed ID: 36652533
[TBL] [Abstract][Full Text] [Related]
8. Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration.
Fowler AJ; Hebron M; Missner AA; Wang R; Gao X; Kurd-Misto BT; Liu X; Moussa CE
Drugs R D; 2019 Jun; 19(2):149-166. PubMed ID: 30919310
[TBL] [Abstract][Full Text] [Related]
9. α-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment.
Karim MR; Liao EE; Kim J; Meints J; Martinez HM; Pletnikova O; Troncoso JC; Lee MK
Mol Neurodegener; 2020 Apr; 15(1):27. PubMed ID: 32299471
[TBL] [Abstract][Full Text] [Related]
10. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
11. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
[TBL] [Abstract][Full Text] [Related]
12. c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease.
Mahul-Mellier AL; Fauvet B; Gysbers A; Dikiy I; Oueslati A; Georgeon S; Lamontanara AJ; Bisquertt A; Eliezer D; Masliah E; Halliday G; Hantschel O; Lashuel HA
Hum Mol Genet; 2014 Jun; 23(11):2858-79. PubMed ID: 24412932
[TBL] [Abstract][Full Text] [Related]
13. Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
Lopez-Cuina M; Guerin PA; Canron MH; Delamarre A; Dehay B; Bezard E; Meissner WG; Fernagut PO
Mov Disord; 2020 Jul; 35(7):1163-1172. PubMed ID: 32291831
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.
Pagan FL; Hebron ML; Wilmarth B; Torres-Yaghi Y; Lawler A; Mundel EE; Yusuf N; Starr NJ; Arellano J; Howard HH; Peyton M; Matar S; Liu X; Fowler AJ; Schwartz SL; Ahn J; Moussa C
Pharmacol Res Perspect; 2019 Apr; 7(2):e00470. PubMed ID: 30906562
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity.
Werner MH; Olanow CW
Mov Disord; 2022 Jan; 37(1):6-15. PubMed ID: 34816484
[TBL] [Abstract][Full Text] [Related]
16. C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease.
Abushouk AI; Negida A; Elshenawy RA; Zein H; Hammad AM; Menshawy A; Mohamed WMY
CNS Neurol Disord Drug Targets; 2018 Apr; 17(1):14-21. PubMed ID: 28571531
[TBL] [Abstract][Full Text] [Related]
17. Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration.
Kim H; Shin JY; Jo A; Kim JH; Park S; Choi JY; Kang HC; Dawson VL; Dawson TM; Shin JH; Lee Y
Brain; 2021 Dec; 144(12):3674-3691. PubMed ID: 34581802
[TBL] [Abstract][Full Text] [Related]
18. Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex.
Boutros SW; Raber J; Unni VK
J Parkinsons Dis; 2021; 11(3):1091-1115. PubMed ID: 34057097
[TBL] [Abstract][Full Text] [Related]
19. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M
Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
[TBL] [Abstract][Full Text] [Related]
20. Endothelial LRP1-ICD Accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 Activation in a Mouse Model of Parkinson's Disease.
Huang R; Gao Y; Duan Q; Zhang Q; He P; Chen J; Ma G; Wang L; Zhang Y; Nie K; Wang L
Mol Neurobiol; 2023 Feb; 60(2):979-1003. PubMed ID: 36394710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
